Zota Health Care Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹163Cr
- +68% YoY
- +14% QoQ
- Net profit
- −₹14Cr
- Q4 FY25: −₹13 Cr
- Margin
- 5%
- +2.5 pp YoY
- +5.3 pp QoQ
Guidance rank: #6 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
3 of 4 strong
The short version
FY27 expansion planned to open 500-700 new stores, mostly COCO format (80%-90%). Zota Healthcare is confident about sustaining a robust growth trajectory driven by both store additions and same-store sales growth.
From Zota Health Care Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY27 expansion planned to open 500-700 new stores, mostly COCO format (80%-90%).
- Moderate store addition pace in Q2 and Q3 to focus on improving store-level profitability.
- Same-store sales growth (SSG) remains strong at ~25%-30%, even without new stores.
- New stores (~800 opened in FY26) are expected to deliver ~100% growth in their second year.
- Continuing store additions in Q1, with ramp-up planned again in Q3 and Q4.
- Confident of sustaining robust growth trajectory if execution on store additions and SSG continues.
- Mature stores show healthy SSG of ~20%-24% annually.
2 more points from Zota Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zota Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The increase in inventory levels and capex amounting to around INR 114 crores for the year is primarily in anticipation of upcoming store openings.
- The company plans to open between 500 to 700 new stores in FY27, with 80%-90% being COCO stores, necessitating capex for store setup.
- Intangible Assets Under Development (approx. INR 14 crores) represent pre-operative expenses like drug licenses and regulatory approvals related to stores under development, indicating ongoing store expansion investments.
2 more points from Zota Health Care Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zota Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As of the recent quarter, Zota Healthcare had around 400–600 stores under process (pipeline) for opening.
- In the previous quarter, approximately 218 stores were launched.
- Around 230–240 stores were already opened from the pipeline in the prior quarter.
- For the current quarter, the company expects to open roughly 200+ additional stores from the remaining pipeline.
- For the financial year FY27, Zota Healthcare plans to open between 500 to 700 stores overall.
2 more points from Zota Health Care Ltd's call on order book
Create a free account to keep reading this call
Zota Health Care Ltd — Quarterly revenue & net profit
Zota Health Care Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 163 | 97 | +68% | 143 | +14% |
| Operating profit (EBITDA) | 9 | 2 | +350% | -0 | — |
| Operating margin | 5% | 2.5% | +2.5 pp | -0.3% | +5.3 pp |
| Profit before tax | -26 | -14 | — | -26 | — |
| Net profit (PAT) | -14 | -13 | — | -30 | — |
| EPS (₹) | -4.09 | -4.50 | — | -8.73 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹199 Cr, net loss ₹26 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zota Health Care's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
Earlier calls (2)
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zota Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zota Health Care Ltd Q4 FY26 results?
FY27 expansion planned to open 500-700 new stores, mostly COCO format (80%-90%). Zota Healthcare is confident about sustaining a robust growth trajectory driven by both store additions and same-store sales growth.
What is Zota Health Care Ltd share price analysis?
Zota Health Care Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹3,918 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zota Health Care Ltd planning capital expenditure?
The increase in inventory levels and capex amounting to around INR 114 crores for the year is primarily in anticipation of upcoming store openings.
Keep Zota Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
